The role of mTOR inhibition in breast cancer is evolving, and ongoing studies are evaluating biomarkers that will identify the patients who will benefit.
Ruth O’Regan, MD
Advertisement
Articles by Ruth O’Regan, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings
2
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
3
Dr Tarantino on the Evolution of TROP2-Directed ADCs in First-Line TNBC
4
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
5